Gastric pathophysiology in gastric cancer
The gastric microbiome changes upon Helicobacter pylori invasion, leading to dysbiosis.
Microbiome changes offer the opportunity to develop new tools for the early diagnosis and treatment of emerging gastric pathologies, including gastric cancer (GC).
The development of GC is orchestrated by a variety of dysregulated molecular processes, including genomic instability, invasion, and uncontrolled proliferation and inflammation in epithelial cells, which, together with stromal interactions, contribute to gastric carcinogenesis.
Using checkpoint inhibitors or chimeric antigen receptors to target gastric tumor cells presents a strategic opportunity to counter immune evasion in GC progression, offering, in combination with chemotherapeutics, potential solutions to enhance the efficacy of anticancer interventions or overcome treatment resistance.
https://www.cell.com/trends/cancer/fulltext/S2405-8033(25)00040-8
